Pandion Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Pandion Therapeutics is a biotechnology company focused on developing bispecific antibody therapies that aim to modulate the immune system directly at disease sites. The approach seeks tissue-specific, durable treatment for autoimmune and inflammatory diseases and for organ transplantation. By targeting therapies to affected tissues, the company intends to reduce reliance on systemic immunosuppression, which can carry safety concerns such as infections and cancer risk, and to improve the durability of response and remission.

The company is based in Cambridge, Massachusetts, and operates in the biotechnology research sector as a mid-sized enterprise. In March 2021, Pandion Therapeutics announced a collaboration with Selexis to develop PT627, an antibody targeting autoimmune and inflammatory diseases. This partnership illustrates the company’s ongoing efforts to advance targeted immunomodulatory therapies.

Sign up for free to view info

Email Format Employee directory